Interesting tech. Trying to make the models used in pre-clinical lab work more accurately reflect the human immune system. Maybe can help in development of next gen immuno-onc agents.
Kind of surprised though you linked a paper this critical of DCVax-L.
While T cell-mediated approaches, including immune checkpoint inhibitors, DCVax, and CAR-T therapies, have shown significant promise in other cancers, there has been limited success with these strategies in glioblastoma (5)
With the reference citation discussing the -L P3 concluding with this sentence:
However, these survival data should be interpreted with caution considering the high crossover rate, a shift in the primary endpoint from PFS to OS, and an inappropriate selection of external controls.
Market Data 
Markets 
AI
